US2021317464A1PendingUtilityA1
Increased nucleic-acid guided cell editing in yeast
Est. expiryJun 25, 2039(~12.9 yrs left)· nominal 20-yr term from priority
C12N 15/102C12N 15/81C12N 15/80C12N 15/1058C12N 2310/20
70
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present disclosure provides methods to increase the percentage of edited yeast cells in a cell population using nucleic-acid guided editing, and automated multi-module instruments for performing these methods.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . A library of editing vectors for performing nucleic acid-guided nuclease editing in yeast, where at least one vector in the library of vectors comprises:
a yeast backbone; an origin of replication; a first non-minimal or non-core constitutive or inducible promoter driving transcription of an editing cassette followed by a terminator element 3′ to the editing cassette, wherein each editing cassette comprises a gRNA sequence and donor DNA sequence; a second non-minimal or non-core constitutive promoter driving transcription for a degron-survival marker fusion gene followed by a terminator element 3′ to the degron-survival marker fusion gene; a third non-minimal constitutive or inducible promoter driving transcription of a nuclease coding sequence with a terminator element 5′ to the nuclease or nuclease fusion coding sequence.
2 . The library of editing vectors of claim 1 , wherein the library of editing vectors comprises a collection of vectors where editing cassettes with different donor DNA sequences are associated with a different barcode.
3 . The library of editing vectors of claim 1 , wherein the library is isothermally assembled.
4 . The library of editing vectors of claim 1 , wherein the minimal promoter is located between −35 to +35 of the transcription start site.
5 . The library of editing vectors of claim 1 , wherein the degron survival marker is an antibiotic.
6 . The library of editing vectors of claim 5 , wherein the antibiotic is selected from the group consisting of hygromycin, blasticidin, kanamycin, and nourseothricin.
7 . The library of editing vectors of claim 1 , wherein the degron-survival marker fusion gene is an ubiquitin-dependent degron.
8 . The library of editing vectors of claim 7 , wherein the ubiquitin-dependent degron is selected from Ura3-d degron, Ubi-R degron, Ubi-M degron, Ubi-Q degron, Ubi-E degron, ZF1 degron, C-terminal phosphodegron; Ts-degron; lt-degron; auxin inducible degron; DD-degron, LID-degron; PSD degron, B-LID degron; and a TIPI degron.
9 . The library of editing vectors of claim 7 , wherein the ubiquitin-dependent degron is a Ura3-d degron.
10 . The library of editing vectors of claim 7 , wherein the first, second, and third non-minimal or non-core constitutive or inducible promoters are the same.
11 . The library of editing vectors of claim 7 , wherein the first, second, and third non-minimal or non-core constitutive or inducible promoters are different.
12 . A library of editing vectors for performing nucleic acid-guided nuclease editing in yeast, where at least one vector in the library of vectors comprises:
a yeast backbone; an origin of replication; a first non-minimal or non-core constitutive or inducible promoter driving transcription of an editing cassette followed by a terminator element 3′ to the editing cassette, wherein each editing cassette comprises a gRNA sequence and donor DNA sequence; a minimal promoter or a weak constitutive promoter driving transcription of a coding sequence for a survival marker gene followed by a terminator element 3′ to the survival marker gene; a second non-minimal or non-core constitutive or inducible promoter driving transcription of a nuclease coding sequence with a terminator element 5′ to the nuclease or nuclease fusion coding sequence.
13 . The library of editing vectors of claim 12 , wherein the library of editing vectors comprises a collection of vectors where editing cassettes with different donor DNA sequences are associated with a different barcode.
14 . The library of editing vectors of claim 122 , wherein the library is isothermally assembled.
15 . The library of editing vectors of claim 122 , wherein the minimal promoter is located between −35 to +35 of the transcription start site.
16 . The library of editing vectors of claim 122 , wherein the minimal promoter is selected from the group consisting of any one of SEQ ID Nos: 1-25.
17 . The library of editing vectors of claim 122 , wherein the weak constitutive promoter is selected from the group consisting of any one of SEQ ID Nos: 26-30.
18 . The library of editing vectors of claim 12 , wherein the survival marker gene is an antibiotic.
19 . The library of editing vectors of claim 18 , wherein the antibiotic is selected from the group consisting of hygromycin, blasticidin, kanamycin, and nourseothricin.
20 . The library of editing vectors of claim 12 , wherein the first and second non-minimal or non-core constitutive or inducible promoters are the same.
21 . The library of editing vectors of claim 12 , wherein the first and second non-minimal or non-core constitutive or inducible promoters are different.Join the waitlist — get patent alerts
Track US2021317464A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.